Metabolic & Cardiometabolic · Gut & Microbiome
intestinal FXR activation suppresses GLP-1
In plain terms: Does the gut bile-acid sensor FXR turn down the appetite-suppressing hormone GLP-1?
Yes — but only shown in animals and the lab so far.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
FXR activation represses proglucagon and blunts SCFA-induced GLP-1 (downregulates FFAR2) — the opposing brake to TGR5. Implies BA-binding dietary fiber (lowering luminal FXR tone) could synergize with SCFA production. Animal/cell-grade.
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Li 2019 · J Cell Physiol | in-vitro | supports | moderate | FXR inversely regulates GLP-1 secretion in STC-1 L-cells by inhibiting CREB transcriptional activity. |
| Pathak P, et al. 2018 · (FXR/TauroLCA) | animal | contradicts | moderate | Intestine-restricted FXR agonist fexaramine INCREASED GLP-1 secretion via TGR5; FXR activation raised GLP-1. |
| Zheng X, et al. 2021 · (HCA) | animal | supports | high | Hyocholic acids raise GLP-1 partly by INHIBITING intestinal FXR (with TGR5 agonism); FXR inhibition boosts GLP-1. |
| Li 2024 · Gut Microbes | animal | supports | moderate | Bacterial GUS-driven bile-acid rise activated ileal FXR and suppressed L-cell GLP-1 |
| Trabelsi MS, et al. 2015 · Nat Commun | animal | supports | high | Landmark FXR in L-cells represses proglucagon+GLP-1; FXR-KO raises GLP-1 (in-vitro+mouse) |
| Ducastel S, et al. 2020 · Sci Rep | animal | supports | high | FXR blunts SCFA-induced GLP-1 by lowering FFAR2 (colonoids+L-cells+mice); FXR-KO raises FFAR2+GLP-1 |
| Stefela 2021 · Front Pharmacol | in-vitro | mixed | low | Dual FXR antagonist/GPBAR1 agonist 7-ELCA stimulates GLP-1 from enteroendocrine cells; FXR blockade favors GLP-1. |
| Pathak 2017 · J Biol Chem | animal | contradicts | moderate | Dual FXR/TGR5 agonist INT-767 stimulated intestinal GLP-1 secretion; FXR activation augmented GLP-1. |
| Yun 2024 · Nat Metab | animal | supports | high | [FT-verified] Yun 2024 NatMetab microbial agmatine FXR agonist promoting PCOS mice; confirms FXR-axis. ANIMAL |
| Lv J et al 2026 · study_type: animal | animal | supports | moderate | Mouse HFD model: BSH-driven UDCA acts as intestinal FXR antagonist + TGR5 agonist, stimulating GLP-1 secretion; GR-7 BSH-inhibitor lowered UDCA and GLP-1. |
| Sun YH et al 2026 · study_type: animal | animal | supports | low | HFD mouse model: LGZG inhibited intestinal FXR-Fgf15 axis while enriching TGR5-agonist/FXR-antagonist bile acids, raising serum GLP-1 (p<0.05) via TGR5, not FXR activation. |
| Stefela 2025 · Pharmacol Res | animal | supports | moderate | FXR antagonist enhanced GLP-1 secretion and improved glucose metabolism in Western-diet mice |
| Niss 2020 · Mol Cell Endocrinol | in-vitro | supports | moderate | [FT-verified] Niss 2020 GLUTag L-cell active FXR represses GLP-1 secretion |
| Kim 2022 · JCI Insight | animal | contradicts | moderate | FXR agonists increased GLP-1+ enteroendocrine cell number/differentiation in intestinal organoids; activation raised GLP-1. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.